ProCE Banner Activity

What’s New Regarding Frontline Combination Regimens in CLL

Clinical Thought
How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.

Released: May 03, 2019

Expiration: May 01, 2020

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics AbbVie

Verastem Oncology

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Seattle Genetics, TG Therapeutics, and Verastem Oncology and funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem Oncology.